chicagoest - BP will be all over this. 

Yes indeed.  But first, we need a successful P2.  Next, we need an emergency authorization, maybe starting with Canada.   Real value begins with FDA approval.  Will take emergency authorization too.  Once medical community and public accept Apabetalone as the choice medication to really return body to true Normal, the value will be there.   Remember we have BTD, does it become easier to receive approval?  My book it should.  Easier with successful P2, without, another study.  Getting too old for another study.  And again, ABL is safe.

With success, at that time, maybe too expensive for BP to acquire.  Consider 200,000,000 taking ABL twice a day.   Or 50,000,000 each year for four years.  Numbers are staggering.   Share price will raise quickly, the float is too small.

Using 250,000,000 shares, annual profit could be with .50 per dose profit margin (just guessing after taxes) twice a day, 40,000,000 patients per year, at six month treatment program, 29 profit per share, multiple of 15, share price 438.  Total value of company over 100 B.  Consider minimum annual dividends of 20 per share, share price of 400.  Dreaming, yes, all the way to the bank.  Lets hope science has it right and my math is correct.  And yes, again will settle for $100 / share.  With C19, the numbers are hard to believe.  Could BP be looking now and seeing the possible results?  Consider the additional value of just one of the other 30 compounds on the shelf is approved.  sidebar

Believe in the Science!